A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00691405 | Completed Phase 2

• 1 other identifier: 091-026
• Study Type: interventional
• Target: 215
• Locations: 1 country
• Sites: 31

Brief Summary

A dose ranging study to evaluate the safety, tolerability and efficacy of arformoterol (given once or twice a day) in subjects with COPD.

Conditions

COPD

Keywords

Arformoterol; (R,R)-formoterol

Outcome Measures

Primary Outcomes (2)

• Part A: The primary efficacy endpoint is the time-normalized area under the FEV1 percent change from pre-dose curve over 12 hours (nAUC0-12) after the first (AM) dose at the 24 hour clinic visit (Visit 4) following 14 days of double-blind treatment.

  Visit 2 (Day 0), Visit 3 (Day 7), Visit 4 (Day 14), Visit 5 (Day 21), Visit 6 (Day 28), Visit 7 (Day 42), Visit 8 (Day 48)

• Part B: The primary efficacy endpoint is the time-normalized area under the FEV1 percent change from pre-dose curve over 24 hours (nAUC0-24) at the 24 hour clinic visit (Visit 7) following 14 days of double-blind treatment.

  Visit 2 (Day 0), Visit 3 (Day 7), Visit 4 (Day 14), Visit 5 (Day 21), Visit 6 (Day 28), Visit 7 (Day 42), Visit 8 (Day 48)

Secondary Outcomes (13)

• Relationship between plasma concentrations of arformoterol and changes in ECG QTc intervals at steady state throughout the dosing interval.

  Visit 2 (Day 0), Visit 3 (Day 7), Visit 4 (Day 14), Visit 5 (Day 21), Visit 6 (Day 28), Visit 7 (Day 42), Visit 8 (Day 48)

• Part A only: Time-normalized area under the curve for FEV1 percent change from pre-dose over 24 hours (nAUC0-24) for each 24 hour clinic visit.

  Visit 2 (Day 0), Visit 3 (Day 7), Visit 4 (Day 14),

• Part B only: Time-normalized area under curve for the FEV1 percent change from pre-dose over 12 hours (nAUC0-12) for each 24 hour clinic visit.

  Visit 5 (Day 21), Visit 6 (Day 28), Visit 7 (Day 42), Visit 8 (Day 48)

• Time-normalized area under the curve for the percent change in FEV1 from pre-dose over 6 hours (nAUC0-6) for the 6 hour clinic visit (Visits 3 and 6).

  Visit 2 (Day 0), Visit 3 (Day 7), Visit 4 (Day 14), Visit 5 (Day 21), Visit 6 (Day 28), Visit 7 (Day 42), Visit 8 (Day 48)

• Percent change in FEV1 from pre-dose to each post dose time point

  Visit 2 (Day 0), Visit 3 (Day 7), Visit 4 (Day 14), Visit 5 (Day 21), Visit 6 (Day 28), Visit 7 (Day 42), Visit 8 (Day 48)

Study Arms (8)

A1

EXPERIMENTAL

Arformoterol 5 mcg BID for 14 days

Drug: Arformoterol tartrate inhalation solution

A2

EXPERIMENTAL

Arformoterol 15 mcg BID for 14 days

Drug: Arformoterol tartrate inhalation solution

A3

EXPERIMENTAL

Arformoterol 25 mcg BID for 14 days

Drug: Arformoterol tartrate inhalation solution

A4

PLACEBO COMPARATOR

Placebo inhalation solution BID for 14 days

Drug: Placebo

B1

EXPERIMENTAL

Arformoterol 15 mcg QD for 14 days

Drug: Arformoterol tartrate inhalation solution

B2

EXPERIMENTAL

Arformoterol 25 mcg QD for 14 days

Drug: Arformoterol tartrate inhalation solution

B3

EXPERIMENTAL

Arformoterol 50 mcg QD for 14 days

Drug: Arformoterol tartrate inhalation solution

B4

PLACEBO COMPARATOR

Placebo inhalation solution QD for 14 days

Drug: Placebo

Interventions

Arformoterol tartrate inhalation solution DRUG

Arformoterol 5 mcg BID

Also known as: (R,R)-formoterol, Brovana

A1

Placebo DRUG

Placebo inhalation solution BID

A4

Eligibility Criteria

• Age: 35 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject may be male or female and must be aged greater than or equal to 35 years on the day the informed consent is signed.
• Female subject less than or equal to 65 years of age must have a serum pregnancy test conducted at study start and confirmed negative. Subjects of childbearing potential must be using an acceptable method of birth control and agree to continue its use throughout the study.
• In order to be considered not of childbearing potential female subjects must be:
• documented surgically sterile (defined as status post-hysterectomy or bilateral tubal ligation) OR
• postmenopausal
• Subject must have a primary diagnosis of COPD, which may include components of chronic bronchitis and/or emphysema. Diagnosis can be made during the screening process.
• Subject must have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years).
• Subject must have a chest x-ray that is consistent with the diagnosis of COPD (e.g., not diagnostic of pneumonia, other infection, atelectasis, or pneumothorax) and taken less than or equal to 6 months before study start. If there is no chest x-ray taken less than or equal to 6 months before study start, a chest x-ray will be performed at Visit 1.
• Subject must be able to complete all study questionnaires and logs reliably.

You may not qualify if:

• A female who is pregnant or lactating.
• Subject who has participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another investigational drug study.
• Subject's schedule or travel prevents the completion of all required visits.
• Subject is scheduled for in-patient hospitalization, including elective surgery (in patient or out-patient) during the trial.
• Subject has had a life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the 30 days prior to study start.
• Subject has a known history of asthma (except childhood asthma) or any chronic respiratory disease (including a current history of sleep apnea) other than COPD (chronic bronchitis and/or emphysema).
• Subject has a known history of alpha 1 antitrypsin deficiency-related emphysema.
• Subject has a history of cancer except non-melanoma skin cancer. Subjects with a history of cancer that is considered surgically cured and without a recurrence within the past 5 years may participate in the study. History of hematologic/lymphatic malignancy treated with chemotherapy or radiation is not allowed, under any condition.
• Subject has a history of lung resection of more than one full lobe or being a recipient of a lung or major organ transplant.
• Subject requires continuous supplemental oxygen therapy (unless subject resides at elevation greater than or equal to 4,000 feet).
• Subject has had a change in dose or type of any medications for COPD within 14 days before the screening visit.
• Subject has a known sensitivity to arformoterol, ipratropium or albuterol or any of the excipients contained in any of these formulations.
• Subject has a history of substance abuse within 12 months of Visit 1, or with a positive urine drug screen at study start.
• Subject is using any prescription drug for which concomitant beta-agonist administration is contraindicated (e.g., beta-blockers).
• Subject has had significant blood loss (\>500 cc) or donated blood within 60 days preceding screening or plans to donate blood during or within 60 days after completing the study.

Sponsors & Collaborators

• Sumitomo Pharma America, Inc.: lead

Study Sites (31)

Unknown Facility

Encinitas, California, United States

Location

Unknown Facility

Long Beach, California, United States

Location

Unknown Facility

Brandon, Florida, United States

Location

Unknown Facility

Cleawater, Florida, United States

Location

Unknown Facility

Fort Lauderdale, Florida, United States

Location

Unknown Facility

Jacksonville, Florida, United States

Location

Unknown Facility

Port Orange, Florida, United States

Location

Unknown Facility

West Palm Beach, Florida, United States

Location

Unknown Facility

Austell, Georgia, United States

Location

Unknown Facility

Topeka, Kansas, United States

Location

Unknown Facility

Marrero, Louisiana, United States

Location

Unknown Facility

New Orleans, Louisiana, United States

Location

Unknown Facility

Opelousas, Louisiana, United States

Location

Unknown Facility

McCook, Nebraska, United States

Location

Unknown Facility

Princeton, New Jersey, United States

Location

Unknown Facility

Hickory, North Carolina, United States

Location

Unknown Facility

Statesville, North Carolina, United States

Location

Unknown Facility

Winston-Salem, North Carolina, United States

Location

Unknown Facility

Columbus, Ohio, United States

Location

Unknown Facility

Eugene, Oregon, United States

Location

Unknown Facility

Medford, Oregon, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, United States

Location

Unknown Facility

Charleston, South Carolina, United States

Location

Unknown Facility

Columbia, South Carolina, United States

Location

Unknown Facility

Simpsonville, South Carolina, United States

Location

Unknown Facility

Spartanburg, South Carolina, United States

Location

Unknown Facility

Austin, Texas, United States

Location

Unknown Facility

San Antonio, Texas, United States

Location

Unknown Facility

Renton, Washington, United States

Location

Unknown Facility

Spokane, Washington, United States

Location

Unknown Facility

Tacoma, Washington, United States

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Formoterol Fumarate

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Ethanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Amines

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 2, 2008
• First Posted: June 5, 2008
• Study Start: October 1, 2003
• Primary Completion: May 1, 2004
• Study Completion: May 1, 2004
• Last Updated: February 22, 2012

Record last verified: 2012-02

Locations

US (31)